dc.contributor.author | Kao, Jia-Horng | |
dc.contributor.author | Fehmi, Tabak | |
dc.contributor.author | Buti, Maria | |
dc.contributor.author | Izumi, Namiki | |
dc.contributor.author | Lim, Young-Suk | |
dc.contributor.author | Janssen, Harry | |
dc.contributor.author | Streinu-Cercel, Adrian | |
dc.contributor.author | Ma, Xiaoli | |
dc.contributor.author | Nurmukhametova, Elena | |
dc.contributor.author | Jablkowski, Maciej | |
dc.contributor.author | Suri, Vithika | |
dc.contributor.author | Flaherty, John F. | |
dc.contributor.author | Lau, Audrey | |
dc.contributor.author | Gaggar, Anuj | |
dc.contributor.author | Mo, Shuyuan | |
dc.contributor.author | Chaudhuri, Abhijit | |
dc.contributor.author | Fung, Scott | |
dc.contributor.author | Chuang, Wan-Long | |
dc.contributor.author | Gane, Edward | |
dc.date.accessioned | 2021-03-03T10:20:22Z | |
dc.date.available | 2021-03-03T10:20:22Z | |
dc.identifier.citation | Buti M., Izumi N., Lim Y., Janssen H., Kao J., Streinu-Cercel A., Nurmukhametova E., Ma X., Fehmi T., Jablkowski M., et al., "Bone and renal safety are improved in chronic HBV patients switched to tenofovir alafenamide (TAF) after either 2 or 3 years of prior tenofovir disoproxil fumarate (TDF) treatment", International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Vienna, Avusturya, 10 - 14 Nisan 2019, cilt.70 | |
dc.identifier.other | av_220bd428-9af7-4beb-946a-53108a8adc33 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/27896 | |
dc.identifier.uri | https://doi.org/10.1016/s0618-8278(19)30903-x | |
dc.language.iso | eng | |
dc.subject | GASTROENTEROLOJİ VE HEPATOLOJİ | |
dc.subject | Klinik Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Tıp | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | İç Hastalıkları | |
dc.subject | Gastroenteroloji-(Hepatoloji) | |
dc.title | Bone and renal safety are improved in chronic HBV patients switched to tenofovir alafenamide (TAF) after either 2 or 3 years of prior tenofovir disoproxil fumarate (TDF) treatment | |
dc.type | Bildiri | |
dc.contributor.department | İstanbul Üniversitesi , , | |
dc.identifier.volume | 70 | |
dc.contributor.firstauthorID | 156023 | |